The CEO of Switzerland’s big pharma company Roche, Severin Schwan, has categorized the launch of the new multiple sclerosis therapy Ocrevus (ocrelizumab) in the first half of 2017 as “particularly pleasing,” a “phenomenal start,” and “even above our own expectations.”
There was strong underlying demand for Ocrevus across its two indications, relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis, Schwan noted
Two other newly launched medicines, the anticancer Alecensa (alectinib), which is indicated for first-line ALK-positive non-small cell lung cancer, and the PD-L1 inhibitor, Tecentriq (atezolizumab), which is available in the US, also did “very well” in
